Curis Lowered to “Neutral” at Zacks (CRIS)
Curis (NASDAQ:CRIS) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research note issued to investors on Tuesday. They currently have a $2.10 price objective on the stock. Zacks‘s price objective points to a potential upside of 25.75% from the company’s current price.
Curis (NASDAQ:CRIS) traded up 0.60% during mid-day trading on Tuesday, hitting $1.68. 698,572 shares of the company’s stock traded hands. Curis has a 52 week low of $1.60 and a 52 week high of $4.74. The stock’s 50-day moving average is $1.78 and its 200-day moving average is $2.30. The company’s market cap is $144.4 million.
Curis (NASDAQ:CRIS) last announced its earnings results on Thursday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. The company had revenue of $4.80 million for the quarter, compared to the consensus estimate of $3.46 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The company’s revenue for the quarter was down 11.1% on a year-over-year basis. Analysts expect that Curis will post $-0.18 EPS for the current fiscal year.
Curis, Inc is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.